open access

Vol 62, No 5 (2011)
Original papers
Published online: 2011-11-08
Submitted: 2013-02-15
Get Citation

The predictive value of the IGF-1 level in acromegaly patients treated by surgery and a somatostatin analogue

Agata Bałdys-Waligórska, Anna Krzentowska-Korek, Filip Gołkowski, Grzegorz Sokołowski, Alicja Hubalewska-Dydejczyk
Endokrynologia Polska 2011;62(5):401-408.

open access

Vol 62, No 5 (2011)
Original papers
Published online: 2011-11-08
Submitted: 2013-02-15

Abstract

Background: We evaluated the predictive value of IGF-1 against hGH in the treatment outcome.
Material and methods: A prospective study was undertaken of 47 patients (mean age 41.1 ± 12.9 years; 44 with macroadenoma and 3 with microadenoma), requiring treatment with octreotide LAR (SSLAR) following incomplete surgery. Concentrations of hGH and IGF-1 were measured three months after surgery and three, six, nine, 12, 18, and 24 months after introducing SSLAR.
Results: Following surgery, respective median values of hGH and IGF-1 concentrations were 5.55 ng/mL (IQR = 7.1) and 512.7 ng/mL (IQR = 379.5). After six, 12, and 24 months of SSLAR treatment, median values of hGH decreased significantly: to 2.95 ng/mL (IQR = 5.5, p < 0.05), 2.95 ng/mL (IQR = 4.4, p < 0.05) and 2.00 ng/mL (IQR = 3.6, p < 0.001), respectively. After six, 12, and 24 months of SSLAR treatment, the respective median IGF-1 concentrations significantly decreased to 384.5 ng/mL (IQR = 312.2, p < 0.01), 323.0 ng/mL (IQR = 230.3, p < 0.001) and 334.0 ng/mL (IQR = 328.9, p < 0.01). The differences between median hGH and IGF-1 concentrations at 12 and 24 months were not significant. A statistically significant correlation was found between IGF-1 concentration prior to and after surgery (R = 0.61, p < 0.05) and prior to SSLAR treatment and IGF-1 concentration 24 months later (R = 0.49, p < 0.05). No such correlation was observed for hGH.
Conclusions: The level of IGF-1 prior to surgery and prior to SSLAR treatment is a better predictor of the treatment outcome than hGH. Octreotide LAR was most effective over the first 12 months of treatment. No further significant decrease of hGH or IGF-1 levels was observed past this period. (Pol J Endocrinol 2011; 62 (5): 401&#8211;408)

Abstract

Background: We evaluated the predictive value of IGF-1 against hGH in the treatment outcome.
Material and methods: A prospective study was undertaken of 47 patients (mean age 41.1 &#177; 12.9 years; 44 with macroadenoma and 3 with microadenoma), requiring treatment with octreotide LAR (SSLAR) following incomplete surgery. Concentrations of hGH and IGF-1 were measured three months after surgery and three, six, nine, 12, 18, and 24 months after introducing SSLAR.
Results: Following surgery, respective median values of hGH and IGF-1 concentrations were 5.55 ng/mL (IQR = 7.1) and 512.7 ng/mL (IQR = 379.5). After six, 12, and 24 months of SSLAR treatment, median values of hGH decreased significantly: to 2.95 ng/mL (IQR = 5.5, p < 0.05), 2.95 ng/mL (IQR = 4.4, p < 0.05) and 2.00 ng/mL (IQR = 3.6, p < 0.001), respectively. After six, 12, and 24 months of SSLAR treatment, the respective median IGF-1 concentrations significantly decreased to 384.5 ng/mL (IQR = 312.2, p < 0.01), 323.0 ng/mL (IQR = 230.3, p < 0.001) and 334.0 ng/mL (IQR = 328.9, p < 0.01). The differences between median hGH and IGF-1 concentrations at 12 and 24 months were not significant. A statistically significant correlation was found between IGF-1 concentration prior to and after surgery (R = 0.61, p < 0.05) and prior to SSLAR treatment and IGF-1 concentration 24 months later (R = 0.49, p < 0.05). No such correlation was observed for hGH.
Conclusions: The level of IGF-1 prior to surgery and prior to SSLAR treatment is a better predictor of the treatment outcome than hGH. Octreotide LAR was most effective over the first 12 months of treatment. No further significant decrease of hGH or IGF-1 levels was observed past this period. (Pol J Endocrinol 2011; 62 (5): 401&#8211;408)
Get Citation

Keywords

acromegaly; somatostatin analogues; octreotide; pituitary; growth hormone; insulin-like growth factor-1

About this article
Title

The predictive value of the IGF-1 level in acromegaly patients treated by surgery and a somatostatin analogue

Journal

Endokrynologia Polska

Issue

Vol 62, No 5 (2011)

Pages

401-408

Published online

2011-11-08

Bibliographic record

Endokrynologia Polska 2011;62(5):401-408.

Keywords

acromegaly
somatostatin analogues
octreotide
pituitary
growth hormone
insulin-like growth factor-1

Authors

Agata Bałdys-Waligórska
Anna Krzentowska-Korek
Filip Gołkowski
Grzegorz Sokołowski
Alicja Hubalewska-Dydejczyk

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl